Pa Januwale 29, 2025, gulu lofufuza la ku China linafalitsa nkhani yotchedwa “Neoadjuvant pyrotinib ndi trastuzumab mu khansa ya m'mawere ya HER2 yomwe sinayankhe msanga (NeoPaTHer): kugwira ntchito bwino, chitetezo, ndi kusanthula kwa biomarker kwa kafukufuku woyembekezeredwa, wokhudzana ndi mayankho ambiri” mu magazini ya “Signal Transduction and Targeted Therapy”.
Khansa ya m'mawere ya Human epidermal growth factor receptor 2 (HER2), yomwe imapanga pafupifupi 15% mpaka 25% ya khansa yonse ya m'mawere, imadziwika kuti ndi mtundu wosiyana komanso woopsa. Imadziwika ndi kuchuluka kwa HER2, receptor ya transmembrane tyrosine kinase yomwe imalimbikitsa kuchulukana kwa maselo a khansa ndikukhala ndi moyo. Odwala omwe ali ndi khansa ya m'mawere ya HER2 ali pachiwopsezo chachikulu chobwereranso ndi kufa poyerekeza ndi omwe ali ndi mitundu ina ya khansa ya m'mawere, zomwe zimapangitsa kuti ikhale matenda ovuta kwambiri kuchiza. Komabe, mawonekedwe a chithandizo cha khansa ya m'mawere ya HER2-positive asintha kwambiri m'zaka makumi awiri zapitazi, makamaka chifukwa cha kuyambitsa mankhwala ochiritsira a HER2. Makamaka, kubwera kwa trastuzumab kwasintha kwambiri njira ya khansa ya m'mawere ya HER2-positive kuchokera ku matenda oopsa kwambiri kupita ku matenda omwe ali ndi zotsatira zochepa komanso zovuta.
Pakati pa Okutobala 2020 ndi Marichi 2022, odwala 129 ochokera m'zipatala zisanu adalembetsa mu kafukufukuyu. Mwa odwala 129 omwe adalembetsa, 62 (48.1%) adadziwika kuti ndi oyankha MRI (gulu A), 26 omwe sanayankhe adapitiliza ndi ma TCbH ena anayi (gulu B), ndipo 41 omwe sanayankhe adalandira pyrotinib yowonjezera (gulu C). Chiŵerengero cha tpCR chinali 30.6% (95% CI: 20.6–43.0%) mu gulu A, 15.4% (95% CI: 6.2–33.5%) mu gulu B, ndi 29.3% (95% CI: 17.6–44.5%) mu gulu C. Kusanthula kwa logistic regression kunawonetsa mwayi wofanana wopeza tpCR pakati pa magulu A ndi C (odds ratio = 1.04, 95% CI: 0.40–2.70). Palibe zochitika zatsopano zoyipa zomwe zidawonedwa powonjezera pyrotinib. Odwala omwe ali ndi kusintha kwa TP53 ndi PIK3CA adawonetsa kuchuluka kochepa kwa mayankho oyamba poyerekeza ndi omwe alibe kapena omwe ali ndi kusintha kwa majini amodzi (36.0% vs. 60.0%, P = 0.08). Zomwe zapezekazi zikusonyeza kuti kuwonjezera pyrotinib kungathandize odwala omwe sayankha ku neoadjuvant trastuzumab kuphatikiza chemotherapy. Kafukufuku wowonjezereka akufunika kuti adziwe zizindikiro za biomarker zomwe zimaneneratu phindu la odwala chifukwa chowonjezera pyrotinib.
Pakadali pano, pali mayesero ambiri azachipatala a ukadaulo watsopano wothana ndi khansa ku China omwe akufuna odwala. Mukafunsira mankhwala ndi ukadaulo watsopano, mutha kulumikizana ndi Dipatimenti Yapadziko Lonse ya Chipatala cha Oncology ku Beijing South Region.
Nambala ya Foni: 4008803716
Email：myimmnet@163.com
Zolemba
https://www.nature.com/articles/s41392-025-02138-6
Nthawi yotumizira: Feb-08-2025